• Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Cision Canada
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • Analytics
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • Analytics
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

New Cholesterol Treatment Now Available for Canadians


News provided by

Sanofi Canada

24 May, 2016, 11:02 ET

Share this article

Share toX

Share this article

Share toX

As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have access to PRALUENT™ 

MONTREAL, May 24, 2016 /CNW Telbec/ - Sanofi Canada is pleased to announce that PRALUENT (alirocumab), solution for subcutaneous injection, is now available in Canada for the treatment of bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C), in certain adult patients.  PRALUENT is indicated as an adjunct to diet and maximally-tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD) who require additional lowering of LDL-C.  The effect of PRALUENT on cardiovascular morbidity and mortality has not been determined.

PRALUENT belongs to a new class of cholesterol medication known as PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitorsi, and was jointly developed by Sanofi and Regeneron Pharmaceuticals.

The arrival of PRALUENT could help address the current gaps in cholesterol treatment and offer an important new option in the management of this disease to patients. High cholesterol is one of the major risk factors for coronary heart disease and strokeii, and despite available treatment, including statins, many Canadian patients face an ongoing challenge of achieving their target LDL-C levels. In fact, approximately 40% of Canadians live with high cholesteroliii and 45% of them do not meet their target LDL-C levelsiv. 

Moreover, according to a 2015 Leger survey* of active Canadian general practitioners, fewer than half (46%) of GPs agree that all of their patients receive the optimal level of care with statins, and almost 8 in 10 (78%) agree that there is a need for additional cholesterol treatments that would work in conjunction with statins.

"The Canadian healthcare provider community is encouraged by the arrival of PRALUENT, given the extensive clinical trial evidence of its ability to dramatically lower LDL – considered bad – cholesterol when used in conjunction with established cholesterol lowering therapies such as statins," said Dr. Shaun Goodman, Staff Cardiologist and Associate Head in the Division of Cardiology, Department of Medicine, at St. Michael's Hospital in Toronto. "The PCSK9 inhibitor class of cholesterol lowering treatment is also characterized by its remarkable safety profile. We anticipate that PCSK9 inhibitors such as PRALUENT will have a significant impact on many Canadian patients living with elevated cholesterol and who cannot currently achieve their cholesterol goals with diet and lifestyle modifications as well as the use of statins."

"Sanofi is tremendously proud to build upon its heritage in cardiovascular therapies to help lead the way towards a new, highly effective and safe form of cholesterol treatment for millions of Canadians," said Niven Al-Khoury, General Manager, Diabetes and Cardiovascular Care, at Sanofi Canada. "The arrival of PRALUENT allows Sanofi to offer a new solution to Canadians struggling to manage their high cholesterol, in particular those living with genetic conditions such as heterozygous familial hypercholesterolemia and patients with high arteriosclerotic risk of cardiovascular disease, who are not achieving the optimal benefit from their current cholesterol therapies."

PRALUENT is available to Canadian patients in two doses (75 mg and 150 mg).  Both are offered in a single 1 milliliter (mL) injection delivered in a single-dose prefilled pen or syringe that patients can self-administer every two weeks.

About PRALUENT 
Alirocumab works by blocking the action of PCSK9, a naturally occurring protein that prevents the liver from clearing LDL cholesterol out of the blood,v,vi,vii thereby allowing the liver to clear more LDL cholesterol from the blood, and so reduces LDL cholesterol levelsi.

The approval of PRALUENT was based on data from the pivotal Phase 3 ODYSSEY program, which included current standard of care therapy (statins) and showed consistent, positive results for PRALUENT when compared to placebo and ezetimibe in reducing LDL-cholesterol. ODYSSEY LONG TERM trial was an 18-months study that evaluated PRALUENT 150 mg every two weeks versus placebo when added to current standard of care, including maximally tolerated statins. ODYSSEY COMBO II trial was a two-year trial that compared PRALUENT with ezetimibe, both added to current standard of care including maximally tolerated statins. Patients received a 75 mg dose of PRALUENT every two weeks, with a dose up-titration to 150 mg at week 12 based on pre-specified criteria.  A proportion of 81.6% of patients remained on their initial dose of 75 mg.

PRALUENT is generally well-tolerated with an acceptable safety profile. Local injection site reactions, including erythema/redness, itching, swelling, or pain/tenderness, where the injection is given were common events (7.2 percent with PRALUENT vs. 5.1 percent with placebo) and resulted in a low discontinuation rate that was comparable to placebo (0.2 percent with PRALUENT vs. 0.4 percent with placebo). Other common adverse events occurring more frequently in patients taking PRALUENT versus placebo included symptoms of the common cold and flu or flu-like symptoms.

ODYSSEY Program
The ODYSSEY Phase 3 program is one of the most comprehensive clinical trial programs ever conducted for an investigational LDL cholesterol lowering therapy. The program includes 14 global Phase 3 trials evaluating more than 23,500 patients, including Canadian participants. The primary efficacy end point in all of the studies was the mean percent reduction from baseline in LDL cholesterol at week 24 compared to control; all of the completed studies met their primary endpoint. A significantly higher proportion of patients achieved a LDL-C of less than 1.8mmol/L in the PRALUENT group as compared to control.  The ongoing ODYSSEY OUTCOMES trial is prospectively evaluating the cardiovascular benefits of PRALUENT in approximately 18,000 patients.

* The Leger study was conducted with an online panel of 50 general practitioners/family doctors across Canada between August 6 and 15, 2015.

About Sanofi – http://www.sanofi.ca¸
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi entities in Canada include the Diabetes and Cardiovascular Diseases Business Unit, the General Medicines, Established Products and Consumer Healthcare Business Unit, Sanofi Pasteur (vaccines), Sanofi Genzyme (rare diseases, multiple sclerosis and oncology) and Merial (animal health). Together they employ close to 1,700 people. In 2015 Sanofi companies invested $133.5 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron commercializes medicines for eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, atopic dermatitis and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Click here to access an infographic.

__________________________

References

i PrPRALUENT™ (alirocumab) Product Monograph, April 2016.
ii http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3484027/k.8419/Heart_disease__High_blood_cholesterol.htm
iii Statistics Canada (2013). Cholesterol levels of Canadians, 2009 to 2011. http://www.statcan.gc.ca/pub/82-625-x/2012001/article/11732-eng.htm. Accessed August 2015.
iv Goodman, S et al. Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS). Can J Cardiol 2010;26(9):e330-e335.
v Konrad RJ, et al. Effects of currently prescribed LDL-C-lowering drugs on PCSK and implications for the next generation of LDL-C-Lowering agents. Lipids Health Dis 2011;10:38.
vi Lagace TA, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Investigation 2006;116(11):2995–3005.
vii Mayne J, et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French- Canadian family and with impaired processing and secretion in cell culture. Clin Chem 2011;57(10):1415–1423.

SOURCE Sanofi Canada

For further information: Catherine R. Cunningham, Sanofi Canada, Tel: 514-956-6120, [email protected]; Maxime-Elisabeth Illick, NATIONAL Public Relations, Tel: 514-843-2322, Cell: 514-475-9131, [email protected]

Modal title

Organization Profile

Sanofi Canada

    Also from this source

  • DUPIXENT® (dupilumab injection) is now approved in Canada for the treatment of adult and adolescent patients (12+) with Eosinophilic Esophagitis

  • Libtayo® (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer

  • Health Canada approves BEYFORTUS™ (nirsevimab) for the prevention of RSV disease in infants

Contact Cision

  • 877-269-7890
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Worldwide Offices

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2023 CNW Group Ltd. All Rights Reserved. A Cision company.